23andMe CEO Anne Wojcicki explains the company's transition to a non-profit and how DNA language models could revolutionize disease prediction. She discusses the challenges of AI-driven drug discovery and opening genetic data to the broader academic community.
Subscribe: https://www.theinformation.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.